InsiderClue
← All stocks

Tango Therapeutics, Inc.

TNGX Scheduled selling only
CIK 0001819133 #1540 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$603.91K
$0.00 on a plan · $603.91K straight out of an exercise
Sold at will
$0.00
0 of 1 sales
Net
−$603.91K
$0.00 against sales at will

By person

15 insiders · 1 transaction
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Crystal Adam
President, R&D
—
$603.91K (1) scheduled
−$603.91K
115,743
0.0686%
$2.59M
−5.6%
Third Rock Ventures IV, L.P. entity
10% owner
—
—
—
13,386,574
7.94%
$299.42M
−20.6%
EcoR1 Capital, LLC entity
10% owner
—
—
—
10,630,736
6.30%
$237.78M
−20.3%
Boxer Capital Management, LLC entity
See remarks
—
—
—
10,301,284
6.11%
$230.41M
−30.8%
Weber Barbara
Director, Executive Chair
—
—
—
1,629,254
0.9663%
$36.44M
+6.1%
Peters Malte
President & CEO
—
—
—
367,500
0.2180%
$8.22M
+3,167%
Beckman Daniella
Chief Financial Officer
—
—
—
184,297
0.1093%
$4.12M
+39.2%
Barry Douglas
General Counsel
—
—
—
66,014
0.0392%
$1.48M
+50.1%
Rothenberg Mace
Director
—
—
—
41,500
0.0246%
$928.23K
+268.9%
Gall Matthew
Chief Financial Officer
—
—
—
40,000
0.0237%
$894.68K
—
Ketchum John B
Director
—
—
—
24,937
0.0148%
$557.77K
+69.8%
Lee Sung
Director
—
—
—
22,870
0.0136%
$511.53K
—
Borisy Alexis
Director
—
—
—
17,500
0.0104%
$391.42K
+55.6%
Calhoun Lesley Ann
Director
—
—
—
16,500
0.0098%
$369.06K
+164.0%
Azelby Robert
Director
—
—
—
5,740
0.0034%
$128.39K
—

Individual transactions

1
Insider
Date
Role
Action
Shares
Price
Amount
Crystal Adam
1 Sep 2026
President, R&D
Sold after exercise
27,000
$22.37
$603.91K

What was left out

Form 4 filings counted 1
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 1
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 27,000
History held since 10 Sep 2020